Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Radiofrequency ablation of neuroendocrine hepatic metastasis. Surg Oncol Clin N Am 2011 Apr;20(2):273-9, vii-viii

Date

03/08/2011

Pubmed ID

21377583

DOI

10.1016/j.soc.2010.11.002

Scopus ID

2-s2.0-79952177514 (requires institutional sign-in at Scopus site)   28 Citations

Abstract

Neuroendocrine cancer commonly metastasizes to the liver and often presents as unresectable disease. Liver resection or debulking most of the tumor provides a survival advantage for patients. Whether used alone or in combination with resection, radiofrequency ablation provides a unique tool to destroy metastases to the liver and spare hepatic parenchyma. Although randomized trials are lacking, retrospective series provide promising data to consider radiofrequency ablation in the management of hepatic neuroendocrine metastases.

Author List

Gamblin TC, Christians K, Pappas SG

Authors

Kathleen K. Christians MD Professor in the Surgery department at Medical College of Wisconsin
Thomas Clark Gamblin MD Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Catheter Ablation
Humans
Liver Neoplasms
Neuroendocrine Tumors